GNTA 5.50 Genenta Science S.p.A.
| Range: | 2.2-7.28 | Vol Avg: | 11628 | Last Div: | 0 | Changes: | -0.23 |
| Beta: | 0.79 | Cap: | 0.10B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Dec 15 2021 | Empoloyees: | 14 | ||
| CUSIP: | 36870W100 | CIK: | 0001838716 | ISIN: | US36870W1009 | Country: | IT |
| CEO: | Mr. Pierluigi Paracchi | Website: | https://www.genenta.com | ||||
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow